Joining Together to Make a Better Future

ViaCyte has a number of key partnerships with commercial, academic and not-for-profit institutions.

Our Partners

CIRM logo

The California Institute for Regenerative Medicine (CIRM) has awarded grants and loans totaling nearly $56M to advance ViaCyte’s development of a stem cell-based therapy for diabetes, and for other related stem cell research.

Cellular Dynamics Logo

Cellular Dynamics International holds a license to certain ViaCyte technology that is applied in the development and production of iCell® Hepatocytes which are human induced pluripotent stem cell derived liver cells.

Thermo Fisher Logo

ViaCyte developed an advanced stem cell growth media that is licensed to Thermo Fisher, formerly Life Technologies, and marketed as StemPro® hESC SFM.

JDRF logo

The JDRF provides financial support for ViaCyte’s research efforts and numerous
ViaCyte collaborators.

Nestle Health Science Logo

Nestlé Institute of Health Sciences (NIHS) has licensed stem cell technology from ViaCyte for basic research purposes. The NIHS is a fundamental research institute located on the campus of the École Polytechnique Fédérale de Lausanne (EPFL) in Switzerland with the primary mission of developing scientific expertise for the advancement of targeted medical nutrition approaches for disease modification and prevention.

Seventh Framework Programme Logo

The Seventh Framework Programme of the European Union has awarded ViaCyte and a team of European collaborators funding for a five year effort to develop novel therapies for diabetes.

STEMCELL Technologies Logo

Under a license to certain ViaCyte patents, StemCell Technologies markets STEMdiff(TM) products for human embryonic and induced pluripotent stem cell differentiation.

Takara Bio Logo

Viacyte licensed to Takara Bio, Inc. certain portions of ViaCyte’s cell differentiation technology to expand Takara’s stem cell product line, marketed under the Cellartis® brand or research purposes only.

Partnering Opportunities

ViaCyte’s expanding intellectual property portfolio enables the development of therapies in areas beyond the Company’s current focus in diabetes. For example, ViaCyte’s hESC technology could be optimal for cell-based screening of candidate pharmaceutical compounds. The Encaptra® drug delivery system could be used in the development of products for life sciences research. ViaCyte welcomes the exploration of research and business opportunities. Please contact us for further information.